Yang Chunyan, Wang Ce, Rong Zhiwei, Xu Zhenyi, Deng Kui, Zhao Weiwei, Cao Lei, Lu Yaxin, Adnan Humara, Li Kang, Hou Yan
Department of Epidemiology and Biostatistics, Public Health School, Harbin Medical University, Harbin, People's Republic of China.
Cancer Manag Res. 2020 Feb 4;12:793-799. doi: 10.2147/CMAR.S232357. eCollection 2020.
Ascites, an accumulation of peritoneal fluid, is associated with poor prognosis of certain cancers. The potential mechanism that ascites worsens prognosis has not been well understood. Lipids have been reported to correlate with the prognosis of patients with epithelial ovarian cancer (EOC). Therefore, we aimed here to investigate whether lipids mediate the effect of ascites on the recurrence of EOC.
We collected the demographic and pathological data of 437 previously untreated patients with EOC to investigate the influence of ascites on recurrence. To identify the mechanism that mediates the potential influence of ascites on recurrence, we used ultra-performance liquid chromatography coupled with mass spectrometry (UPLC-MS) to determine the plasma lipid profiles of 53 patients with EOC. We used mediation analysis to evaluate if lipids mediated the effects of ascites on the recurrence of EOC.
Patients with ascites had a poorer prognosis, which was associated with higher levels of carbohydrate antigen-CA125 (CA125) and FIGO stage. We identified six different lipid metabolites that were associated with ascites and recurrence. Mediation analysis revealed that the lipids LysoPC(P-15:0), PC(P-34:4), and PC(38:6) may mediate the effects of ascites on recurrence.
Our findings suggest that LysoPC(P-15:0), PC(P-34:4), and PC(38:6) mediate the effect of ascites on the prognosis of patients with EOC. We believe therefore that it is reasonable to consider metabolic interventions targeting the metabolism of LysoPC(P-15:0), PC(P-34:4), and PC(38:6) as a palliative treatment for patients with EOC with ascites. Further studies of more patients will be required to validate our findings.
腹水是腹膜液的积聚，与某些癌症的不良预后相关。腹水恶化预后的潜在机制尚未完全明确。据报道，脂质与上皮性卵巢癌（EOC）患者的预后相关。因此，我们旨在研究脂质是否介导腹水对EOC复发的影响。
我们收集了437例未经治疗的EOC患者的人口统计学和病理数据，以研究腹水对复发的影响。为了确定介导腹水对复发潜在影响的机制，我们使用超高效液相色谱-质谱联用（UPLC-MS）来测定53例EOC患者的血浆脂质谱。我们使用中介分析来评估脂质是否介导了腹水对EOC复发的影响。
有腹水的患者预后较差，这与较高水平的糖类抗原CA125（CA125）和国际妇产科联盟（FIGO）分期有关。我们鉴定出六种与腹水和复发相关的不同脂质代谢物。中介分析显示，脂质溶血磷脂酰胆碱（LysoPC）（P-15:0）、磷脂酰胆碱（PC）（P-34:4）和PC（38:6）可能介导腹水对复发的影响。
我们的研究结果表明，LysoPC（P-15:0）、PC（P-34:4）和PC（38:6）介导了腹水对EOC患者预后的影响。因此，我们认为将针对LysoPC（P-15:0）、PC（P-34:4）和PC（38:6）代谢的代谢干预作为有腹水的EOC患者的姑息治疗是合理的。需要对更多患者进行进一步研究以验证我们的发现。
